

Targeting Long Non-Coding RNAs Binding to EZH2 for Reduced Cancer or Associated Diseases

Kanchan Kumari and Sandip K. Mishra*

**Department of Cancer Biology, Cancer Biology Lab, Institute of Life Sciences (Department of Biotechnology), Bhubaneswar, India*

Received July 27, 2020; Revised August 19, 2020; Accepted August 21, 2020

ABSTRACT

Enhancer of Zeste Homolog 2 (EZH2) is a polycomb group protein that tri-methylates its target genes at histone 3 position thereby leading to their transcriptional silencing. Acting as a global repressor, EZH2 has major implications in tumorigenesis and other ailments. Indispensable role of EZH2 in epigenetics has led the researchers to identify various ways that may be used to regulate it. Among these strategies, microRNA, small-interfering RNA and short-hairpin RNA has been successfully applied to regulate the expression of EZH2. In recent years, after genetic and epigenetic regulation, role of long non-coding RNA (lncRNA) has emerged as a new level of biological regulation. Recently, lncRNAs have been found to be function through EZH2 and its downstream target genes. In the present review, we discuss the mechanistic insights into the potential role of lncRNA-EZH2 axis in disease pathogenesis as reported and indexed in PubMed in the current year. Including various types of human cancer, we also analyzed other disorders where lncRNA-EZH2 axis plays defining role in disease progression.

Keywords: EZH2, lncRNAs, Oncogenes, Tumor suppressor genes, Cancer

INTRODUCTION

EZH2 is the catalytic subunit of polycomb repressive complex 2 (PRC2) that have multifaceted role normal as well as cancerous cell development. Predominantly, EZH2 functions as an oncogene and regulates several genes that have tumor suppressive role. By tri-methylating the promoter elements at histone H3 at position lysine 27, EZH2 act as an epigenetic regulator that have multiple cellular functions [1-4]. Highly expressed in human malignancies, EZH2 stimulates transformation of normal cells into cancerous [5-8]. Owing to its critical role in cellular functions, various levels of regulation has been studied that regulate epigenetic modifications performed by EZH2 specially H3K27me3. These regulations include microRNA [9-14], small-interfering RNA [15-17], short-hairpin RNA [18-20] and long non-coding RNAs [21]. Long non-coding RNAs are more than 200 nucleotides long that are transcribed by RNA polymerase II and do not code for any protein. These non-coding RNAs play variety of roles to regulate gene expression and modulate phenotype of cells. They act as chromatin modifiers and have essential role in epigenetic inheritance. Having modulatory role in cardiovascular diseases and multiple human malignancies, lncRNAs demonstrate a complex layer of gene regulation both transcriptional and posttranscriptional [22]. Based on their position in genomes and in relation to well known-

protein coding genes, lncRNAs have been broadly categorized in five major types [23]. First among these are stand-alone lncRNAs that include large intergenic ncRNAs or lincRNAs and do not overlap protein-coding genes such as HOTAIR, Xist and MALAT1. Second category is natural antisense transcripts, which are transcribed opposite to the sense strand of known gene-coding transcripts and overlap to some extent to form sense-antisense pairs, examples of this kind are Xist/Tsix and Kcnq1/Kcnq1ot1. Other three lncRNAs include pseudogenes, long intronic ncRNAs and promoter-associated transcripts and enhancer RNAs [22, 23].

Here we discuss the category of lncRNAs that exhibit their functions by regulating polycomb group protein EZH2 and its upstream or downstream targets. Recent studies report a

Corresponding authors: Sandip K. Mishra, Scientist-F, Cancer Biology Laboratory, Department of Cancer Biology, Institute of Life Sciences, Bhubaneswar, Odisha, India, Tel: +919437180218, +917978123687; E-mail: sandipkmishra@hotmail.com

Citation: Kumari K. & Mishra SK. (2020) Targeting Long Non-Coding RNAs Binding to EZH2 for Reduced Cancer or Associated Diseases. J Pharm Drug Res, 3(4): 427-432.

Copyright: ©2020 Kumari K & Mishra SK. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

large number of lncRNA that regulate EZH2 in different cancers and other disease conditions. In the following section, we review the regulation of EZH2 by several lncRNAs that play influential role in pathophysiology of diseases/ disorders that include all cancer types such as breast, prostate, NSCLC (non-small cell lung cancer), osteosarcoma, ovarian, endometrial, colorectal, gastric, pancreatic, uveal melanoma, esophageal squamous cell carcinoma, colon cancer, anaplastic thyroid carcinoma, glioma, hepatocellular carcinoma and others. Role of lncRNAs in other disease conditions such as preeclampsia, hypoxia, sepsis, vascularization, Allergic rhinitis and atherosclerosis were also analyzed. Based on their function, lncRNA can be oncogenic or tumor suppressive.

ONCOGENIC LNCRNAs

Upregulated expression of lncRNA HOTAIR leads to EZH2-mediated down-regulation of miRNA-106 in preeclampsia placental tissue [24]. In another study, down-regulation of HOTAIR results into increased expression of miR-138-5p which in turn reduced the expression of EZH2 leading to chemosensitivity of Cisplatin resistant ovarian cancer cells [25]. Moreover, HOTAIR induced EZH2 expression leads to enhanced expression of collagen and α -SMA and at the same time reduced miR-34a expression plays influential role on myofibroblast phenotype and thus in Systemic Sclerosis (SSc) [26]. In NSCLC, down-regulation of anti-differentiation non-coding RNA (ANCR) leads to reduced expression of EZH2 and increased expression of tumor suppressor p21 and p27 [27]. HIF-1 α plays major role in hypoxia, a well-known feature of tumor microenvironment. lncRNA HIF-1 α inhibitor at translation level (HITT) inhibits the expression of HIF-1 α by stimulating increased recruitment of EZH2 on its promoter affecting hypoxia-induced apoptosis in tumor microenvironment [28]. In breast cancer cells, lncRNA named differentiation antagonizing non-protein coding RNA (DANCR) regulates the EZH2-mediated epigenetic silencing of suppressor of cytokine signaling 3 (SOCS3) [29]. Increased tissue and plasma level of lncRNA PCAT (Prostate-cancer-associated ncRNA transcript 1) in endometrial carcinoma is associated with EZH2 intervened expression of E-cadherin [30]. Interfering lncRNA Zeb-anti-sense (AS) 1 in combination with EZH2 leads to reduced osteosarcoma cell proliferation, migration and enhanced apoptosis [31] similar to colorectal carcinoma (CRC) [32] where, in association with EZH2, lncRNA CACNA1G-AS1 regulated the expression of p53 to induce increased proliferative and invasive properties [33]. In osteosarcoma, lncRNA human homeobox A transcript at the distal tip (HOTTIP) play important role. HOTTIP are potentially upregulated in osteosarcoma tissues as well as cell lines and induces xenograft growth and lung metastasis. By recruiting EZH2 and lysine specific demethylase (LSD1) on LATS2 promoter, HOTTIP activates YAP/ β -catenin signaling leading to increased osteosarcoma growth [34].

lncRNA actin filament associated protein 1-antisense RNA1 (AFAP1-AS1) binds directly to EZH2 to regulate the expression of Kruppel-like factor 2 (KLF2) which in turn affects gastric cancer cell growth and proliferation [35]. Another lncRNA that plays important role in gastric cancer cell progression is large tumor suppressor kinase 2 antisense transcript 1 (LATS2-AS1-001). Upon binding with EZH2, LATS2-AS1-001 induces the phosphorylation of YAP thereby inhibiting gastric cancer progression [36]. lncRNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) regulates the expression of BRCA1 by recruiting EZH2 and stimulating AKT phosphorylation thereby aggravating sepsis progression [37]. Similarly, in hepatocellular carcinoma (HCC), in cooperation with EZH2, MALAT1 regulates the expression of miR-22, E-cadherin and Snail family transcriptional repressor 1 (SNAIL) elucidating the underlying mechanism of MALAT1-mediated increased HCC progression and metastasis [38]. Another lncRNA urothelial carcinoma antigen-1 (UCA1) regulates vascular smooth muscle cell growth and migration by stimulating EZH2 recruitment on promoter of matrix metalloproteinase-9 leading to its repression [39]. By increasing the interaction of CDK1, EZH2 and its downstream target nuclear factor of activated T (NFAT), lncRNA UCA1 also play influential role in arsenic-induced cell toxicity [40]. Yet another oncogenic role of lncRNA UCA1 was evident in gastric cancer where it promoted cisplatin resistance in gastric cancer cells [41]. Upregulated expression level of lncRNA NRON, a repressor of NFAT in breast cancer samples and cells is oncogenic that induces EZH2 expression leading to increase breast cancer cell growth and metastasis [42]. On the other hand, lncRNA LOXL1-AS1 interacts with EZH2 to repress miR-708-5p expression that directly regulates nuclear factor kappa B (NFkB) to induce increased breast cancer progression [43]. Bekric et al. reviewed the functional significance of lncRNAs that in association with chromatin modifying enzymes such as EZH2 play important regulatory role in biliary tract cancer [44].

Upon interaction with EZH2, lncRNA small nucleolar RNA host gene 14 (SNHG14) regulates the expression of epithelial cell marker E-cadherin to induce increased cell invasion in pancreatic carcinoma [45]. Competitive binding of lncRNA proteasome subunit α 3 antisense 1 to miRNA-101, a direct negative regulator of EZH2, has been elucidated to promote esophageal squamous cell proliferation, migration and invasion in vitro [46]. lncRNA CDKN2B-AS1 (cyclin dependent kinase inhibitor 2B antisense 1) is highly expressed in atherosclerosis, a leading cause of cardiovascular diseases. CDKN2B-AS1 promotes plaque formation by stimulating EZH2 recruitment on CDKN2B promoter thereby inhibiting its tumor suppressive role [47]. Increased expression of lncRNA long non-coding RNA associated with poor prognosis of colon cancer (LNAPPCC) is associated with poor survival of colon cancer

patients. Upon binding, LNAPPCC inhibits EZH2-mediated repression of protocadherin 7 (PCDH7) which in turn activates LNAPPCC via ERK/c-FOS signaling forming a positive regulatory loop [48]. DLEU2 or deleted in lymphocytic leukemia 2 is a lncRNA that is highly expressed in human hepatocellular carcinoma and is expressed in liver. It binds directly to Hepatitis B protein HBx and polycomb group protein EZH2 leading to hepatocytes transformation [49]. LncRNA associated with poor prognosis of hepatocellular carcinoma (AWPPH) plays oncogenic role in hepatocellular carcinoma by repressing tumor suppressor gene PTEN by stimulating increased occupancy of EZH2 and LSD on its promoter [50]. Yet another lncRNA lymphoid enhancer-binding factor-1 antisense RNA 1 (LEF1-AS1) induces increased hepatocellular cancer cell growth by increasing the expression of EZH2 and cell division cycle-associated 7 (CDCA7) [51]. EZH2-mediated epigenetic silencing of LINC00632 leads to silencing of lncRNA cerebellar degeneration-related 1 antisense (CDR1 AS) which in turn regulates miR-7 playing critical role in metastasis in melanoma [52].

TUMOR SUPPRESSIVE LNCRNAS

By inhibiting EZH2, LncRNA Growth Arrest Specific 5 (LncGAS5) alters the balance of Th1/Th2 differentiation, which contributes to the immune response in Allergic rhinitis patients [53]. LncRNA GAS5 plays anti-tumorigenic role in melanoma cells by recruiting E2F to EZH2 promoter thereby inhibiting its occupancy on CDKN1C [54], a well-known tumor suppressor. Similar tumor suppressive role of

LncRNA GAS5 was found in glioma where it was found to directly interact with EZH2 to alleviate the expression of miR-424 leading to suppressed malignant phenotypes [55]. However, in atherosclerosis, LncRNA GAS5 promotes lipid accumulation by inhibiting ATP-binding cassette transporter A1 (ABCA1) expression upon binding to EZH2 [56]. Another anti-tumor lncRNA is Prader Willi/ Angelman region RNA 5(PAR5) that reduces EZH2 expression and its binding to E-cadherin to inhibit anaplastic thyroid carcinoma progression [57]. LncRNA GATA antisense 1 (GATA-AS1) show anti-tumor activity in gastric cancer. By stimulating increased occupancy of EZH2 on promote region of Frizzled 4 protein associated with Wnt/ β -catenin signaling, GATA-AS1 inhibits gastric cancer progression [58]. Reduced expression of BLACAT1 (bladder cancer associated transcript 1) is prostate cancer tissues and cell lines were observed and LncRNA (BLACAT1) inhibited prostate cancer cell proliferation by interacting with miR-361 and binding to EZH2 which in turn binds to mitogen-activated protein kinase and regulates cancer cell growth [59]. In acute myeloid leukemia (AML), lncRNA NR-104098 inhibits proliferation and induces differentiation of AML cells by recruiting E2F on promoter of EZH2 thereby repressing its transcription [60]. In uveal melanoma, low expression of LncRNA SNHG7 is associated with poor prognosis, as it inhibits malignant transformation by repressing polycomb group protein EZH2 [61]. However, in ovarian cancer, SNHG7 is activated by specificity protein 1 (SP1) and exhibits oncogenic properties by regulating EZH2-mediated KLF2 expression [62].




Figure 1. Intricate relation of lncRNAs and EZH2.

CONCLUSIONS

LncRNAs have emerged as important gene regulators that regulate gene transcription in nucleus and alter mRNA

stability and posttranslational modifications in cytoplasm [63]. Representing to a highly heterogeneous group of transcripts, lncRNAs function by binding to transcription

factors or DNA binding proteins, histone modifying complexes or to enzymes like RNA polymerases [64-66]. LncRNAs recruit PRC2 complex to promoter elements of gene specific chromatin thereby regulating the overall cellular functions [67] as an oncogene or as a tumor suppressor. As discussed, several studies report binding of lncRNAs to EZH2, which affects its recruitment to its target genes leading to severe pathological consequences (**Figure 1**). Thus, targeting EZH2 binding lncRNAs may prove to be beneficial for disease management.

REFERENCES

1. Sashida G, Iwama A (2017) Multifaceted role of the polycomb-group gene EZH2 in hematological malignancies. *Int J Hematol* 105(1): 23-30.
2. Khan SN, Jankowska AM, Mahfouz R, Dunbar AJ, Sugimoto Y, et al. (2013) Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies. *Leukemia* 27(6): 1301-1309.
3. Alzrigat M, Jernberg-Wiklund H, Licht JD (2018) Targeting EZH2 in Multiple Myeloma-Multifaceted Anti-Tumor Activity. *Epigenomes* 2(3).
4. Yamaguchi H, Hung MC (2014) Regulation and Role of EZH2 in Cancer. *Cancer research and treatment. J Korean Cancer Assoc* 46(3): 209-222.
5. Gan L, Yang Y, Li Q, Feng Y, Liu T, et al. (2018) Epigenetic regulation of cancer progression by EZH2: From biological insights to therapeutic potential. *Biomark Res* 6: 10.
6. Kim KH, Roberts CW (2016) Targeting EZH2 in cancer. *Nat Med* 22(2): 128-134.
7. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, et al. (2003) EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. *Proc Nat Acad Sci USA* 100(20): 11606-11611.
8. Beguelin W, Popovic R, Teater M, Jiang Y, Bunting KL, et al. (2013) EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. *Cancer Cell* 23(5): 677-692.
9. Alajez NM, Shi W, Hui AB, Bruce J, Lenarduzzi M, et al. (2010) Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98. *Cell Death Dis* 1:e85.
10. Guo Y, Ying L, Tian Y, Yang P, Zhu Y, et al. (2013) miR-144 downregulation increases bladder cancer cell proliferation by targeting EZH2 and regulating Wnt signaling. *The FEBS J* 280(18): 4531-4538.
11. Zhang H, Zhang H, Zhao M, Lv Z, Zhang X, et al. (2013) MiR-138 inhibits tumor growth through repression of EZH2 in non-small cell lung cancer: Cellular physiology and biochemistry. *Int J Exp Cell Physiol Biochem Pharmacol* 31(1): 56-65.
12. Qiu S, Huang D, Yin D, Li F, Li X, et al. (2013) Suppression of tumorigenicity by microRNA-138 through inhibition of EZH2-CDK4/6-pRb-E2F1 signal loop in glioblastoma multiforme. *Biochimica et Biophysica Acta* 1832(10): 1697-1707.
13. Zhang JG, Guo JF, Liu DL, Liu Q, Wang JJ (2011) MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2. *J Thorac Oncol* 6(4): 671-678.
14. Banerjee R, Mani RS, Russo N, Scanlon CS, Tsodikov A, et al. (2011) The tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2 overexpression in invasive squamous cell carcinoma. *Oncogene* 30(42): 4339-4349.
15. Xia H, Zhang W, Li Y, Guo N, Yu C (2014) EZH2 silencing with RNA interference induces G2/M arrest in human lung cancer cells in vitro. *BioMed Res Int* 2014: 348728.
16. Xia H, Yu CH, Zhang Y, Yu J, Li J, et al. (2012) EZH2 silencing with RNAi enhances irradiation-induced inhibition of human lung cancer growth in vitro and in vivo. *Oncol Lett* 4(1): 135-140.
17. Bryant RJ, Cross NA, Eaton CL, Hamdy FC, Cunliffe VT (2007) EZH2 promotes proliferation and invasiveness of prostate cancer cells. *Prostate* 67(5): 547-556.
18. Lu F, Xu H, Wang Q, Li M, Meng J, et al. (2018) Inhibition of enhancer of zeste homolog 2 increases the expression of p16 and suppresses the proliferation and migration of ovarian carcinoma cells in vitro and in vivo. *Oncol Lett* 15(3): 3233-3239.
19. Shen JK, Cote GM, Gao Y, Choy E, Mankin HJ, et al. (2016) Targeting EZH2-mediated methylation of H3K27 inhibits proliferation and migration of Synovial Sarcoma in vitro. *Sci Rep* 6: 25239.
20. Etchegaray JP, Yang X, DeBruyne JP, Peters AH, Weaver DR, et al. (2006) The polycomb group protein EZH2 is required for mammalian circadian clock function. *J Biol Chem* 281(30): 21209-21215.
21. Su M, Xiao Y, Tang J, Wu J, Ma J, et al. (2018) Role of lncRNA and EZH2 Interaction/Regulatory Network in Lung Cancer. *J Cancer* 9(22): 4156-4165.
22. Ma L, Bajic VB, Zhang Z (2013) On the classification of long non-coding RNAs. *RNA Biol* 10(6): 925-933.

23. Kung JT, Colognori D, Lee JT (2013) Long noncoding RNAs: Past, present, and future. *Genetics* 193(3): 651-669.
24. Zhao YH, Liu YL, Fei KL, Li P (2020) Long non-coding RNA HOTAIR modulates the progression of preeclampsia through inhibiting miR-106 in an EZH2-dependent manner. *Life Sci* 253: 117668.
25. Zhang Y, Ai H, Fan X, Chen S, Wang Y, et al. (2020) Knockdown of long non-coding RNA HOTAIR reverses cisplatin resistance of ovarian cancer cells through inhibiting miR-138-5p-regulated EZH2 and SIRT1. *Biol Res* 53(1): 18.
26. Wasson CW, Abignano G, Hermes H, Malaab M, Ross RL, et al. (2020) Long non-coding RNA HOTAIR drives EZH2-dependent myofibroblast activation in systemic sclerosis through miRNA 34a-dependent activation of NOTCH. *Ann Rheum Dis* 79(4): 507-517.
27. Zhou T, Fang JJ, Zhou YX, Li ZP, Jiang L, et al. (2020) Long non-coding RNA ANCR promotes progression of NSCLC by inhibiting E-Ca expression. *Eur Rev Med Pharmacol Sci* 24(3): 1250-1257.
28. Wang X, Wang Y, Li L, Xue X, Xie H, et al. (2020) A lncRNA coordinates with Ezh2 to inhibit HIF-1 α transcription and suppress cancer cell adaption to hypoxia. *Oncogene* 39(9): 1860-1874.
29. Zhang KJ, Tan XL, Guo L (2020) The long non-coding RNA DANCR regulates the inflammatory phenotype of breast cancer cells and promotes breast cancer progression via EZH2-dependent suppression of SOCS3 transcription. *Mol Oncol* 14(2): 309-328.
30. Zhang C, Shao S, Zhang Y, Wang L, Liu J, et al. (2020) LncRNA PCAT1 promotes metastasis of endometrial carcinoma through epigenetical downregulation of E-cadherin associated with methyltransferase EZH2. *Life Sci* 243: 117295.
31. Zhang B, Fan DB, Liu L, Qin Y, Feng DQ (2020) Knockdown of ZEB2-AS1 inhibits cell proliferation, invasion and induces apoptosis in osteosarcoma by combining with EZH2. *Eur Rev Med Pharmacol Sci* 24(12): 6533-6539.
32. Wu X, Zhu H, Xie Y, Gu X, Zhang L, et al. (2020) Knockdown of ZEB2-AS1 inhibits cell invasion and induces apoptosis in colorectal cancer. *J BUON* 25(1): 194-201.
33. Wei LJ, Bai DM, Wang ZY, Liu BC (2020) Upregulated lncRNA CACNA1G-AS1 aggravates the progression of colorectal cancer by downregulating p53. *Eur Rev Med Pharmacol Sci* 24(1): 130-136.
34. Liu K, Ni JD, Li WZ, Pan BQ, Yang YT, et al. (2020) The Sp1/FOXC1/HOTTIP/LATS2/YAP/beta-catenin cascade promotes malignant and metastatic progression of osteosarcoma. *Mol Oncol*.
35. Yuan XH, Li J, Cao Y, Jie ZG, Zeng YF (2020) Long non-coding RNA AFAP1-AS1 promotes proliferation and migration of gastric cancer by downregulating KLF2. *Eur Rev Med Pharmacol Sci* 24(2): 673-680.
36. Sun D, Wang Y, Wang H, Xin Y (2020) The novel long non-coding RNA LATS2-AS1-001 inhibits gastric cancer progression by regulating the LATS2/YAP1 signaling pathway via binding to EZH2. *Cancer Cell Int* 20: 204.
37. Yong H, Wu G, Chen J, Liu X, Bai Y, et al. (2020) lncRNA MALAT1 Accelerates Skeletal Muscle Cell Apoptosis and Inflammatory Response in Sepsis by Decreasing BRCA1 Expression by Recruiting EZH2. *Mol Ther Nucl Acids* 19: 97-108.
38. Chen S, Wang G, Tao K, Cai K, Wu K, et al. (2020) Long noncoding RNA metastasis-associated lung adenocarcinoma transcript 1 cooperates with enhancer of zeste homolog 2 to promote hepatocellular carcinoma development by modulating the microRNA-22/Snail family transcriptional repressor 1 axis. *Cancer Sci* 111(5): 1582-1595.
39. Xu Z, Zuo Z, Dong D, Liu J, Tang Y, et al. (2020) Downregulated lncRNA UCA1 accelerates proliferation and migration of vascular smooth muscle cells by epigenetic regulation of MMP9. *Exp Ther Med* 19(6): 3589-3594.
40. Dong Z, Gao M, Li C, Xu M, Liu S (2020) LncRNA UCA1 Antagonizes Arsenic-Induced Cell Cycle Arrest through Destabilizing EZH2 and Facilitating NFATc2 Expression. *Adv Sci* 7(11): 1903630.
41. Dai Q, Zhang T, Pan J, Li C (2020) LncRNA UCA1 promotes cisplatin resistance in gastric cancer via recruiting EZH2 and activating PI3K/AKT pathway. *J Cancer* 11(13): 3882-3892.
42. Xiong T, Huang C, Li J, Yu S, Chen F, et al. (2020) LncRNA NRON promotes the proliferation, metastasis and EMT process in bladder cancer. *J Cancer* 11(7): 1751-1760.
43. Dong HT, Liu Q, Zhao T, Yao F, Xu Y, et al. (2020) Long Non-coding RNA LOXL1-AS1 Drives Breast Cancer Invasion and Metastasis by Antagonizing miR-708-5p Expression and Activity. *Mol Ther Nucl Acids* 19: 696-705.
44. Bekric D, Neureiter D, Ritter M, Jakab M, Gaisberger M, et al. (2020) Long Non-Coding RNAs in Biliary Tract Cancer-An Up-to-Date Review. *J Clin Med* 9(4).
45. Xie F, Huang Q, Wang C, Chen S, Liu C, et al. (2020) Downregulation of long noncoding RNA SNHG14

- suppresses cell proliferation and invasion by regulating EZH2 in pancreatic ductal adenocarcinoma (PDAC). *Cancer Biomark* 27(3): 357-364.
46. Qiu BQ, Lin XH, Ye XD, Huang W, Pei X, et al. (2020) Long non-coding RNA PSMA3-AS1 promotes malignant phenotypes of esophageal cancer by modulating the miR-101/EZH2 axis as a ceRNA. *Aging (Albany NY)* 12(2): 1843-1856.
 47. Ou M, Li X, Zhao S, Cui S, Tu J (2020) Long non-coding RNA CDKN2B-AS1 contributes to atherosclerotic plaque formation by forming RNA-DNA triplex in the CDKN2B promoter. *EBioMedicine* 55:102694.
 48. Li T, Li Z, Wan H, Tang X, Wang H (2020) Recurrence-Associated Long Non-coding RNA LNAPCC Facilitates Colon Cancer Progression via Forming a Positive Feedback Loop with PCDH7. *Mol Ther Nucl Acids* 20: 545-557.
 49. Salerno D, Chiodo L, Alfano V, Floriot O, Cottone G, et al. (2020) Hepatitis B protein HBx binds the DLEU2 lncRNA to sustain cccDNA and host cancer-related gene transcription. *Gut* 2019: 319637.
 50. Guo D, Liu F, Zhang L, Bian N, Liu L, et al. (2020) Long non-coding RNA AWPPH enhances malignant phenotypes in nasopharyngeal carcinoma via silencing PTEN through interacting with LSD1 and EZH2. *Biochem Cell Biol; Biochimie et biologie cellulaire*.
 51. Gao J, Dai C, Yu X, Yin XB, Zhou F (2020) LncRNA LEF1-AS1 silencing diminishes EZH2 expression to delay hepatocellular carcinoma development by impairing CEBPB-interaction with CDCA7. *Cell Cycle* 19(8): 870-883.
 52. Hanniford D, Ulloa-Morales A, Karz A, Berzoti-Coelho MG, Moubarak RS, et al. (2020) Epigenetic Silencing of CDR1as Drives IGF2BP3-Mediated Melanoma Invasion and Metastasis. *Cancer Cell* 37(1):55-70 e15.
 53. Zhu X, Wang X, Wang Y, Zhao Y (2020) Exosomal long non-coding RNA GAS5 suppresses Th1 differentiation and promotes Th2 differentiation via downregulating EZH2 and T-bet in allergic rhinitis. *Mol Immunol* 118: 30-39.
 54. Xu W, Yan Z, Hu F, Wei W, Yang C, et al. (2020) Long non-coding RNA GAS5 accelerates oxidative stress in melanoma cells by rescuing EZH2-mediated CDKN1C downregulation. *Cancer Cell Int* 20:116.
 55. Jin C, Zhao J, Zhang ZP, Wu M, Li J, et al. (2020) Long non-coding RNA GAS5, by up-regulating PRC2 and targeting the promoter methylation of miR-424, suppresses multiple malignant phenotypes of glioma. *J Neuro-oncol* 148: 529-543.
 56. Meng XD, Yao HH, Wang LM, Yu M, Shi S, et al. (2020) Knockdown of GAS5 Inhibits Atherosclerosis Progression via Reducing EZH2-Mediated ABCA1 Transcription in ApoE (-/-) Mice. *Mol Ther Nucl Acids* 19: 84-96.
 57. Pellicchia S, Sepe R, Decaussin-Petrucci M, Ivan C, Shimizu M, et al. (2020) The Long Non-Coding RNA Prader Willi/Angelman Region RNA5 (PAR5) Is Downregulated in Anaplastic Thyroid Carcinomas Where It Acts as a Tumor Suppressor by Reducing EZH2 Activity. *Cancers* 12(1).
 58. Li ZT, Zhang X, Wang DW, Xu J, Kou KJ, et al. (2020) Overexpressed lncRNA GATA6-AS1 Inhibits LNM and EMT via FZD4 through the Wnt/beta-Catenin Signaling Pathway in GC. *Mol Ther Nucl Acids* 19: 827-840.
 59. Li HY, Jiang FQ, Chu L, Wei X (2020) Long non-coding RNA BLACAT1 inhibits prostate cancer cell proliferation through sponging miR-361. *Eur Rev Med Pharmacol Sci* 24(1): 74-85.
 60. Feng Y, Hu S, Li L, Zhang S, Liu J, et al. (2020) LncRNA NR-104098 Inhibits AML Proliferation and Induces Differentiation Through Repressing EZH2 Transcription by Interacting With E2F1. *Front Cell Dev Biol* 8: 142.
 61. Wu X, Yuan Y, Ma R, Xu B, Zhang (2020) lncRNA SNHG7 affects malignant tumor behaviors through downregulation of EZH2 in uveal melanoma cell lines. *Oncol Lett* 19(2): 1505-1515.
 62. Bai Z, Wu Y, Bai S, Yan Y, Kang H, et al. (2020) Long non-coding RNA SNHG7 Is activated by SP1 and exerts oncogenic properties by interacting with EZH2 in ovarian cancer. *J Cell Mol Med* 24(13): 7479-7489.
 63. Fang Y, Fullwood MJ (2016) Roles, functions, and mechanisms of long non-coding RNAs in cancer. *Genom Prot Bioinform* 14(1): 42-54.
 64. Long Y, Wang X, Youmans DT, Cech TR (2017) How do lncRNAs regulate transcription? *Sci Adv* 3(9): eaao2110.
 65. Liu SJ, Horlbeck MA, Cho SW, Birk HS, Malatesta M, et al. (2017) CRISPRi-based genome-scale identification of functional long noncoding RNA loci in human cells. *Science* 355(6320).
 66. D GH, Kelley DR, Tenen D, Bernstein B, Rinn JL (2016) Widespread RNA binding by chromatin-associated proteins. *Gen Biol* 17: 28.
 67. Davidovich C, Zheng L, Goodrich KJ, Cech TR (2013) Promiscuous RNA binding by Polycomb repressive complex 2. *Nat Struct Mol Biol* 20(11): 1250-1257.